

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10590054
Filing Date	2006-08-21
First Named Inventor	Jacob WESTMAN et al
Art Unit	1645
Examiner Name	
Attorney Docket Number	WESTMAN=3

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button							Add	
NON-PATENT LITERATURE DOCUMENTS							Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Ts

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10590054
Filing Date	2006-08-21
First Named Inventor	Jacob WESTMAN et al
Art Unit	1645
Examiner Name	
Attorney Docket Number	WESTMAN=3

1	Abstracts of Papers Part 2, 226th ACS National Meeting, American Chemical Society, New York, NY, September 7-11, 2003.	<input type="checkbox"/>
2	NAHI, H. et al, "Effects of PRIMA-1 on Chronic Lymphocytic Leukemia cells with and without hemizygous p53 deletion". British Journal of Haematology, vol. 127, 2004, pp. 285-291.	<input type="checkbox"/>
3	NIELSEN, Arnold T., "Systems with Bridgehead Nitrogen. beta-Ketols of the 1-Azabicyclo[2.2.2]octane Series", Journal of Organic Chemistry, vol. 31, April 1966, pp. 1053-1059.	<input type="checkbox"/>
4	OKUDA, Yoshinobu et al., "Regulatory role of p53 in experimental autoimmune encephalomyelitis", Journal of Neuroimmunology, vol. 135, 2003, pp. 29-37.	<input type="checkbox"/>
5	REHMAN, Abdur et al., "Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells", Breast Cancer Research, vol. 7, No. 5, 2005, pp. R765-R774.	<input type="checkbox"/>
6	SAKAMURI, Sukumar et al., "Synthesis of 2-alkyl-3-aryl-substituted quinuclidines as novel dopamine transporter inhibitors", Tetrahedron Letters, vol. 41, 2000, pp. 9949-9952.	<input type="checkbox"/>
7	SCHIEWECK, Frank et al., "Synthesis of geminal bis(hydroxymethyl)pyrrolidine and pyrrolizidine imino sugars", J. Chem. Soc., Perkin Trans. 1, 2001, pp. 3409-3414.	<input type="checkbox"/>
8	SEKHAR, Konjeti et al., "NADPH Oxidase Activity Is Essential for Keap1/Nrf2-mediated Induction of GCLC in Response to 2-Indol-3-yl-methylenequinuclidin-3-ols", Cancer Research, vol. 63, September 1, 2003, pp. 5636-5645.	<input type="checkbox"/>
9	SHERR, Charles J., "Tumor surveillance via the ARF-p53 pathway", Genes & Dev., vol. 12, 1998, pp. 2984-2991.	<input type="checkbox"/>
10	SINGH, Tara et al., "Antimalarials. Some Quinuclidine Derivatives of 7-Chloro-4-aminoquinoline and 6-Methoxy-8-aminoquinoline", Research Laboratories of Aldrich Chemical Company, Vol. 12, May 1969, pp. 524-526.	<input type="checkbox"/>
11	SYMONDS, Holly et al., "p53-Dependent Apoptosis Suppresses Tumor Growth and Progression In Vivo", Cell, Vol. 78, August 26, 1994, pp.703-711.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10590054
Filing Date	2006-06-21
First Named Inventor	Jacob WESTMAN et al
Art Unit	1645
Examiner Name	
Attorney Docket Number	WESTMAN=3

12	TONDER, Janne E., "Exploring the Stereoselectivity in the Peterson Reaction of Several 2-Substituted 1-Azabicyclo [2.2.2]octan-3-ones", <i>Tetrahedron</i> , vol. 56., 2000, pp. 1139-1146.	<input type="checkbox"/>
13	VOROB'EVA, et al., "Reaction of 2-Methylene-3-Oxoquinuclidine with Nucleophilic Reagents", <i>Chemistry of Heterocyclic Compounds</i> , vol. 10, 1977, pp. 1098-1104.	<input type="checkbox"/>
14	YANINA, A.D., et al., "Synthesis and pharmacological properties of 2- and 2,3-substituted quinuclidines", <i>1-Pharmacology</i> , vol. 108, 1988, p. 71.	<input type="checkbox"/>
15	BARDEESY, Nabeel et al., "Clonal Expansion and Attenuated Apoptosis in Wilms' Tumors Are Associated with p53 Gene Mutations", <i>Cancer Research</i> , vol. 55, January 15, 1995, pp. 215-219.	<input type="checkbox"/>
16	BENNETT, Martin et al., "Cell Surface Trafficking of Fas: A Rapid Mechanism of p53-Mediated Apoptosis", <i>Science</i> , vol. 282, October 9, 1998, pp. 290-293.	<input type="checkbox"/>
17	BEROUD et al., "p53 gene mutation: software and database", <i>Nucleic Acids Research</i> , Vol. 26, No. 1, 1998, pp. 200-204.	<input type="checkbox"/>
18	BONAFE et al., "The different apoptotic potential of the p53 codon 72 alleles increases with age and modulates in vivo ischaemia-induced cell death", <i>Cell Death and Differentiation</i> , vol. 11, 2004, pp. 962-973.	<input type="checkbox"/>
19	BONDARENKO et al., "Synthesis and antiarrhythmic activity of derivatives of 3-aminoquinuclidine and 2-(aminomethyl) Quinuclidine", <i>Pharmaceutical Chemistry Journal</i> , vol. 12., 1978, pp. 1452-1455.	<input type="checkbox"/>
20	BYKOV et al., "Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database", <i>Carcinogenesis</i> , vol. 23, No. 12, 2002, pp. 2011-2018.	<input type="checkbox"/>
21	BYKOV et al., "Novel cancer therapy by reactivation of the p53 apoptosis pathway", <i>Annals of Medicine</i> , vol. 35, 2003, pp. 458-465	<input type="checkbox"/>
22	BYKOV et al., "PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis", <i>Oncogene</i> , 2005, pp. 1-8.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10590054
Filing Date	2006-08-21
First Named Inventor	Jacob WESTMAN et al
Art Unit	1645
Examiner Name	
Attorney Docket Number	WESTMAN=3

23	BYKOV, et al , "Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs", The Journal of Biological Chemistry, vol. 280, No. 34, August 26, 2005, pp. 30384-30391.	<input type="checkbox"/>
24	BYKOV et al., "Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound", Nature Medicine, vol. 8, no. 3, March 2002, pp. 282-288.	<input type="checkbox"/>
25	BYKOV et al., "Small molecules that reactivate mutant p53", European Journal of Cancer, vol. 39, 2003, pp. 1828-1834.	<input type="checkbox"/>
26	CHAKRABARTI et al., "Rearrangement of 2-[1(3H)-Oxodihydrobenzo[c]FURAN-3-YL] Quinuclidin-3-Ones to Tetrahydrobenzo[b]Quinolizines. A novel Synthesis of Benzo[b]Quinolizine Ring Systems", Tetrahedron Letters, Vol. 26, No. 35, 1985, pp. 4245-4246.	<input type="checkbox"/>
27	CHIPUK et al., "Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription", Cancer Cell, vol. 4, November 2003, pp. 371-381.	<input type="checkbox"/>
28	EVAN et al., "A Matter of Life and Cell Death", Science, vol. 281, August 28, 1998, pp. 1317-1322.	<input type="checkbox"/>
29	FISHER et al., "The Fused Quinuclidine-valerolactone system", Tetrahedron, vol. 31, 1975, pp. 317-325.	<input type="checkbox"/>
30	GOTTLIEB et al., "p53 and Apoptosis", Cancer Biology, Vol. 8, 1998, pp. 359-368.	<input type="checkbox"/>
31	KO et al., "p53: puzzle and paradigm", Genes & Development, vol. 10, 1996, pp. 1054-1072.	<input type="checkbox"/>
32	KUMAR et al., "Clay Catalyzed Highly Selective O-Alkylation of Primary Alcohols with Orthoesters", Tetrahedron Letters, Vol. 38, No. 20, 1997, pp. 3619-3622.	<input type="checkbox"/>
33	LANGER et al., "New Methods of Drug Delivery", SCIENCE, vol. 249, No. 4976, September 28, 1990, pp. 1527-1533.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10590054
Filing Date	2006-08-21
First Named Inventor	Jacob WESTMAN et al
Art Unit	1645
Examiner Name	
Attorney Docket Number	WESTMAN=3

34	LEE et al., "Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells", Biochemical and Biophysical Research Communications, vol. 349, 2006, pp. 1117-1124.	<input type="checkbox"/>
35	LI et al., "Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway", Mol Cancer Ther, vol. 4, no.6, June 2005, pp. 901-909.	<input type="checkbox"/>
36	LIANG et al., "Functional p53 blocks progestin-induced VEGF expression in human breast cancer cells", Dalton cardiovascular Research Center and the Dept. of Biomedical Sciences, University of Missouri, Columbia, MO,	<input type="checkbox"/>
37	LOWE, III et al., "2-Aryl-azabicyclo[2.2.2]octanes as Novel Nonpeptide Substance P Antagonists", Bioorganic & Medicinal Chemistry Letters, vol. 4, no. 6, 1994, pp. 839-842.	<input type="checkbox"/>
38	LOWE et al., "p53 Status and the Efficacy of Cancer Therapy in Vivo", Science, New Series, Vol. 266, No. 5186, November 4, 1994, pp. 807-810.	<input type="checkbox"/>
39	MYERS et al., "A New Family of Small Molecules to Probe the Reactivation of Mutant p53", J. Am. Chem. Soc., July 15, 2004.	<input type="checkbox"/>
40	MORGAN et al., "Synthesis and Cardiac Electrophysiological Activity of 2- and 3-[(Substituted phenyl)alkyl] quinuclidines. Structure-Activity Relationships", J. Med. Chem., Vol. 30, 1987, pp. 2259-2269.	<input type="checkbox"/>
41	MOUNTZ et al., "Defective clonal deletion and anergy induction in TCR transgenic lpr/lpr mice", Immunology, Vol. 6, 1994, pp. 27-37.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10590054
Filing Date	2006-06-21
First Named Inventor	Jacob WESTMAN et al
Art Unit	1645
Examiner Name	
Attorney Docket Number	WESTMAN=3

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/jmf/	Date (YYYY-MM-DD)	2007-05-25
Name/Print	Jay M. Finkelstein	Registration Number	21,082

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 216(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.